Growth factors used to accelerate engraftment after hematopoietic cell transplantation can increase the severity of graft-versus-host disease. Experiments with mice examine how irradiation, used to prepare recipients for transplants, contributes to this problem (pages 436–441).
This is a preview of subscription content, log in via an institution to check access.
Kim Caesar
References
Morris, E.S. et al. Nat. Med. 15, 436–441 (2009).
Offner, F. et al. Blood 88, 4058–4062 (1996).
Dekker, A. et al. J. Clin. Oncol. 24, 5207–5215 (2006).
Ringden, O. et al. J. Clin. Oncol. 22, 416–423 (2004).
Ho, V.T. et al. Bone Marrow Transplant. 32, 771–775 (2003).
Khoury, H.J. et al. Blood 107, 1712–1716 (2006).
Grewal, S.S., Barker, J.J., Davies, S.M. & Wagner, J.E. Blood 101, 4233–4244 (2003).
Rocha, V. et al. N. Engl. J. Med. 342, 1846–1854 (2000).
Gluckman, E. et al. Exp. Hematol. 32, 397–407 (2004).
Hagglund, H. et al. Bone Marrow Transplant. 24, 831–836 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Martin, P. Choosing between GVHD and delayed engraftment. Nat Med 15, 363–364 (2009). https://doi.org/10.1038/nm0409-363
Issue Date:
DOI: https://doi.org/10.1038/nm0409-363
- Springer Nature America, Inc.